The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 8:28 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #91. Johnson & Johnson Aragon Pharmaceuticals

Acquirer: Johnson & Johnson (NYSE:JNJ)
Acquiree: Aragon Pharmaceuticals
Details: Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, today announced a definitive agreement with Johnson & Johnson whereby Aragon will be acquired for $650 million in cash up front along with $350 million in contingent development milestone payments that could bring the total transaction value to $1 billion. The acquisition includes Aragon's androgen receptor antagonist program, including its most advanced compound, ARN-509, a second generation androgen receptor signaling inhibitor that is currently being evaluated in a Phase II trial in patients with castration-resistant prostate cancer.

Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.

Johnson and Johnson SEC Filing Email Alerts Service


Open the JNJ Page at The Online Investor »

Company Name: 
Johnson & Johnson
Stock buyback: 
JNJ buyback
Website: 
www.jnj.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding JNJ: 
131
Total Market Value Held by ETFs: 
$56.06B
Total Market Capitalization: 
$300.37B
% of Market Cap. Held by ETFs: 
18.66%
 

Open the JNJ Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree JNJ Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.94 out of 4)
18th percentile
(ranked lower than approx. 82% of all stocks covered)

Analysts' Target Price:
JNJ Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 91 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.